

CALMARE THERAPEUTICS Inc
Form SC 13G/A
February 14, 2019

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. _____) *

Calmare Therapeutics

(Name of Issuer)

Common Stock

(Title of Class of Securities)

204512107

(CUSIP Number)

December 31, 2018

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: CALMARE THERAPEUTICS Inc - Form SC 13G/A

CUSIP No. 204512107

1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

Bard Associates, Inc. 36-3452497

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) / /
(b) / /

3. SEC Use Only

4. Citizenship or Place of Organization

Illinois

| | | |
|----------------|----|--------------------------|
| Number of | 5. | Sole Voting Power |
| Shares | | |
| Beneficially | | 500,000 |
| Owned by | | ----- |
| Each Reporting | 6. | Shared Voting Power |
| Person with | | 0 |
| | | ----- |
| | 7. | Sole Dispositive Power |
| | | 2,500,025 |
| | | ----- |
| | 8. | Shared Dispositive Power |
| | | 0 |
| | | ----- |

9. Aggregate Amount Beneficially Owned by Each Reporting Person

2,500,025

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions) / /

Edgar Filing: CALMARE THERAPEUTICS Inc - Form SC 13G/A

11. Percent of Class Represented by Amount in Row (9)

6.4%

12. Type of Reporting Person (See Instructions)

IA

ITEM 1.

(a) Name of Issuer

Calmare Therapeutics

(b) Address of Issuer's Principal Executive Offices

1375 Kings Highway East
Fairfield, CT 06824

ITEM 2.

(a) Name of Person Filing

Bard Associates, Inc.

(b) Address of Principal Business Office or, if none, Residence

135 South LaSalle Street, Suite 3700
Chicago, IL 60603

(c) Citizenship

United States

(d) Title of Class of Securities

Common Stock

(e) CUSIP Number

204512107

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTIONS
240.13d-1(b) or 240.13d-2(b) or (c), CHECK WHETHER THE
PERSON FILING IS A:

(a) / / Broker or dealer registered under section 15 of
The Act (15 U.S.C. 78o).

Edgar Filing: CALMARE THERAPEUTICS Inc - Form SC 13G/A

- (b) / / Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) / / Insurance company as defined in section 3(a)(19) Of the Act (15. U.S.C. 78c).
- (d) / / Investment company registered under section 8 of The Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) / x / An investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);
- (f) / / An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);
- (g) / / A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);
- (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) / / A church plan that is excluded from the definition of an Investment company under section 3(c)(14) of the Investment Company Act of 1940 (15. U.S.C. 80a-3);
- (j) / / Group, in accordance with Section 240.13d-1(b)(1)(ii)(J).

ITEM 4. OWNERSHIP

The amount of shares beneficially owned set forth in Item 4(a) is comprised of 2,500,025 common shares held by Bard. The information reported below in the Item 4 is as of December 31, 2018. The percentage set forth in Item 4(b) is calculated based on the 38,997,971 shares of the Issuer's Common Stock outstanding as of February 13,2018, as reported in the Issuer's Proxy Materials filed July 2,2018.

- (a) Amount beneficially owned:
2,500,025
- (b) Percent of Class
6.4%
- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote
500,000

 - (ii) Shared power to vote or to direct the vote
0

 - (iii) Sole power to dispose or to direct the disposition of

Edgar Filing: CALMARE THERAPEUTICS Inc - Form SC 13G/A

2,500,025

(iv) Shared power to dispose or to direct the disposition of

0

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

If this statement is being filed to report the fact that as of the date hereof
The reporting person has ceased to be the beneficial owner of more than five
Percent of the class of securities, check the following / /.

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF
ANOTHER PERSON

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY
WHICH ACQUIRED THE SECURITY BEING REPORTED ON
BY THE PARENT HOLDING COMPANY OR CONTROL PERSON

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE
GROUP

ITEM 9. NOTICE OF DISSOLUTION OF GROUP

ITEM 10. CERTIFICATION

By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were acquired and are held in the
ordinary course of business and were not acquired and are not held for
the purpose of or with the effect of changing or influencing the control of
the issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having that purpose
or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true,
complete and correct.

2/13/2019

Date

/s/ Timothy B. Johnson

Signature

Timothy B. Johnson/ President

Name/Title